99 related articles for article (PubMed ID: 24113674)
1. Population pharmacokinetic-pharmacodynamic modeling of haloperidol in patients with schizophrenia using positive and negative syndrome rating scale.
Pilla Reddy V; Kozielska M; Johnson M; Mafirakureva N; Vermeulen A; Liu J; de Greef R; Rujescu D; Groothuis GM; Danhof M; Proost JH
J Clin Psychopharmacol; 2013 Dec; 33(6):731-9. PubMed ID: 24113674
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetic-pharmacodynamic modeling of antipsychotic drugs in patients with schizophrenia Part I: the use of PANSS total score and clinical utility.
Pilla Reddy V; Kozielska M; Suleiman AA; Johnson M; Vermeulen A; Liu J; de Greef R; Groothuis GM; Danhof M; Proost JH
Schizophr Res; 2013 May; 146(1-3):144-52. PubMed ID: 23473810
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetic-pharmacodynamic modelling of antipsychotic drugs in patients with schizophrenia: part II: the use of subscales of the PANSS score.
Pilla Reddy V; Kozielska M; Suleiman AA; Johnson M; Vermeulen A; Liu J; de Greef R; Groothuis GM; Danhof M; Proost JH
Schizophr Res; 2013 May; 146(1-3):153-61. PubMed ID: 23473811
[TBL] [Abstract][Full Text] [Related]
4. Modelling and simulation of the Positive and Negative Syndrome Scale (PANSS) time course and dropout hazard in placebo arms of schizophrenia clinical trials.
Pilla Reddy V; Kozielska M; Johnson M; Suleiman AA; Vermeulen A; Liu J; de Greef R; Groothuis GM; Danhof M; Proost JH
Clin Pharmacokinet; 2012 Apr; 51(4):261-75. PubMed ID: 22420580
[TBL] [Abstract][Full Text] [Related]
5. Population pharmacokinetic/pharmacodynamic model of clozapine for characterizing the relationship between accumulated exposure and PANSS scores in patients with schizophrenia.
Shang DW; Li LJ; Wang XP; Wen YG; Ren YP; Guo W; Li WB; Li L; Zhou TY; Lu W; Wang CY
Ther Drug Monit; 2014 Jun; 36(3):378-86. PubMed ID: 24342896
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of iloperidone in the short-term treatment of schizophrenia: a post hoc analysis of pooled patient data from four phase III, placebo- and active-controlled trials.
Citrome L; Meng X; Hochfeld M; Stahl SM
Hum Psychopharmacol; 2012 Jan; 27(1):24-32. PubMed ID: 22161738
[TBL] [Abstract][Full Text] [Related]
7. [Erythrocyte ketone reductase activity, total plasma haloperidol and acute psychoses].
Dutoit D; Thomas P; Leroux JM; Vaiga G; Pommery J; Cottencin O; Erb F; Goudemand M
Encephale; 1995; 21(6):417-24. PubMed ID: 8674466
[TBL] [Abstract][Full Text] [Related]
8. Oral versus injectable antipsychotic treatment in early psychosis: post hoc comparison of two studies.
Emsley R; Oosthuizen P; Koen L; Niehaus DJ; Medori R; Rabinowitz J
Clin Ther; 2008 Dec; 30(12):2378-86. PubMed ID: 19167596
[TBL] [Abstract][Full Text] [Related]
9. Prediction of the outcome of a phase 3 clinical trial of an antischizophrenic agent (quetiapine fumarate) by simulation with a population pharmacokinetic and pharmacodynamic model.
Kimko HC; Reele SS; Holford NH; Peck CC
Clin Pharmacol Ther; 2000 Nov; 68(5):568-77. PubMed ID: 11103759
[TBL] [Abstract][Full Text] [Related]
10. Beneficial antipsychotic effects of allopurinol as add-on therapy for schizophrenia: a double blind, randomized and placebo controlled trial.
Akhondzadeh S; Safarcherati A; Amini H
Prog Neuropsychopharmacol Biol Psychiatry; 2005 Feb; 29(2):253-9. PubMed ID: 15694232
[TBL] [Abstract][Full Text] [Related]
11. Amoxapine as an antipsychotic: comparative study versus haloperidol.
Chaudhry IB; Husain N; Khan S; Badshah S; Deakin B; Kapur S
J Clin Psychopharmacol; 2007 Dec; 27(6):575-81. PubMed ID: 18004123
[TBL] [Abstract][Full Text] [Related]
12. Impact of clinical pharmacokinetics on neuroleptic therapy in patients with schizophrenia.
Midha KK; Hubbard JW; Marder SR; Marshall BD; Van Putten T
J Psychiatry Neurosci; 1994 Jul; 19(4):254-64. PubMed ID: 7918346
[TBL] [Abstract][Full Text] [Related]
13. Exploratory analyses of efficacy data from schizophrenia trials in support of new drug applications submitted to the US Food and Drug Administration.
Khin NA; Chen YF; Yang Y; Yang P; Laughren TP
J Clin Psychiatry; 2012 Jun; 73(6):856-64. PubMed ID: 22687813
[TBL] [Abstract][Full Text] [Related]
14. First generation antipsychotics switch with Risperidone in the treatment of chronic schizophrenic patients.
Popović I; Ravanić D; Popović V; Vladejić S; Stanojević A; Stojanović M
Psychiatr Danub; 2011 Dec; 23(4):384-8. PubMed ID: 22075740
[TBL] [Abstract][Full Text] [Related]
15. Long-term efficacy and safety of iloperidone: results from 3 clinical trials for the treatment of schizophrenia.
Kane JM; Lauriello J; Laska E; Di Marino M; Wolfgang CD
J Clin Psychopharmacol; 2008 Apr; 28(2 Suppl 1):S29-35. PubMed ID: 18334910
[TBL] [Abstract][Full Text] [Related]
16. The efficacy, safety, and tolerability of aripiprazole for the treatment of schizoaffective disorder: results from a pooled analysis of a sub-population of subjects from two randomized, double-blind, placebo-controlled, pivotal trials.
Glick ID; Mankoski R; Eudicone JM; Marcus RN; Tran QV; Assunção-Talbott S
J Affect Disord; 2009 May; 115(1-2):18-26. PubMed ID: 19230981
[TBL] [Abstract][Full Text] [Related]
17. Modeling Approach with Therapeutic Drug Monitoring Data to Describe Time Course of Clozapine Exposure and Positive and Negative Syndrome Scale Scores.
Park SI; Kim S; Kim MG; Lim HS; Kim E
Ther Drug Monit; 2023 Jun; 45(3):417-424. PubMed ID: 36097334
[TBL] [Abstract][Full Text] [Related]
18. Joint modeling of dropout and outcome in three pivotal clinical trials of schizophrenia.
Levine SZ; Goldberg Y; Samara M; Davis JM; Leucht S
Schizophr Res; 2015 May; 164(1-3):122-6. PubMed ID: 25790904
[TBL] [Abstract][Full Text] [Related]
19. Obsessive-compulsive symptoms and disorder in patients with schizophrenia treated with clozapine or haloperidol.
Sa AR; Hounie AG; Sampaio AS; Arrais J; Miguel EC; Elkis H
Compr Psychiatry; 2009; 50(5):437-42. PubMed ID: 19683614
[TBL] [Abstract][Full Text] [Related]
20. Trajectories and antecedents of treatment response over time in early-episode psychosis.
Levine SZ; Rabinowitz J
Schizophr Bull; 2010 May; 36(3):624-32. PubMed ID: 18849294
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]